Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Extended Drug Therapy for Hepatitis Is Challenged
Patients who do not initially respond to standard drug therapy for treatment of hepatitis C are unlikely to respond to long-term maintenance therapy as well, according to a new study. Yet many patients who do not at first respond to drugs are placed on

Gilead Sciences, Inc. (GILD) Release: Data Demonstrating Significant Efficacy of Viread(R) in Treating Chronic Hepatitis B Published in New England Journal of Medicine
FOSTER CITY, Calif.--(BUSINESS WIRE)-- (Nasdaq: GILD) today announced the publication of detailed 48-week data from two Phase III pivotal clinical trials evaluating the safety and efficacy of its once-daily Viread (tenofovir disoproxil fumarate) for the

Interferon as long-term treatment for hepatitis C not effective
Results of the 3-year study, called the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear in today's issue of . The researchers found no difference in the rate of progression of liver disease among patients who received

UPDATES AND COMMENTARY RSS Feed

Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....

Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...

New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....

Recenti Prog Med 1998 May;89(5):241-4

Effect of blood letting on serum aminotransferase levels of patients with chronic hepatitis C and iron overload.

Girelli CM, Mirata C, Casiraghi A

Unita Operativa di Medicina I, Ospedale, Busto Arsizio, Varese.

OBJECTIVE: To confirm the existing evidence that blood letting reduces serum aminotransferase levels and to seek factors associated with a greater reduction in subjects with chronic hepatitis C and iron overload.

DESIGN: Prospective, open label, non controlled study in two northern Italian hospitals.

PATIENTS: Sixteen patients with histologically proven chronic hepatitis, positive hepatitis C virus serology, HCV-RNA detectable in their sera, and histological and biochemical signs of iron overload, nonresponders to interferon alpha therapy, underwent weekly phlebotomies until serum ferritin values < or = 50 ng/mL were obtained. Serum aminotransferases, serum ferritin and transferrin saturation were then measured and compared with values at baseline.

RESULTS: Alanine aminotransferase and aspartate aminotransferase levels fell after phlebotomies from 193 +/- 107 IU/L to 115 +/- 53 IU/L (t = 4.94, p = 0.0001) and from 124 +/- 60 IU/L to 85 +/- 35 IU/L (t = 3.76, p = 0.002), respectively. The magnitude of the reduction correlated with baseline aminotransferase levels (r = 0.68, p = 0.004 for alanine aminotransferase and r = 0.63, p = 0.009 for aspartate aminotransferase), but not with those of serum ferritin and transferrin saturation percentage, nor with the quantity of iron removed. There was a trend towards a greater alanine aminotransferase reduction in patients with the highest baseline serum ferritin (r = 0.26, p = 0.14).

CONCLUSIONS: Blood letting was effective in reducing serum aminotransferase levels of patients with chronic hepatitis C and iron overload, especially those with the highest baseline aminotransferase levels.

PMID: 9676130, UI: 98340781

table Of Contents

Hepatitis Central

http://hepatitis-central.com

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 05 Dec 2008